Jonathan Finn
Jonathan Finn's purchase track record
Jonathan Finn has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/10/2024 | ATOS | $44K | -31.4% | -20.0% | +12.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Cibus Partners with Crystal Crop Protection for Mustard Traits. Cibus has agreed to collaborate with Crystal Crop Protection to develop gene-edited traits for mustard crops in India. This partnership aims to improve Brassica Juncea varieties, marking a strategic step in the company's agricultural technology efforts. The stock is currently trading near its 52-week low, with recent technical signals indicating high volatility.
Transaction History
| ATOS | ▲ Buy | Grant | 10,000 | $0 | 5/12/2026 | View on chart |
| ATOS | ▲ Buy | Open Market | 25,000 | $44K | 4/10/2024 | View on chart |
| CBUS | ▲ Buy | Grant | 1,206 | — | 5/31/2023 | View on chart |
| CBUS | ▲ Buy | Grant | 1,143,949 | — | 5/31/2023 | View on chart |
| CBUS | ▲ Buy | Grant | 118,893 | — | 5/31/2023 | View on chart |
| CBUS | ▲ Buy | Grant | 13,405 | — | 5/31/2023 | View on chart |
| CBUS | ▲ Buy | Grant | 1,505,967 | — | 5/31/2023 | View on chart |
| CBUS | ▲ Buy | Grant | 12,048 | — | 5/31/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Atossa Announces Stapled CVR Plan and Raises Price Target
Atossa Therapeutics has unveiled a plan to issue a stapled convertible voting rights (CVR) linked to potential rare pediatric disease priority review voucher proceeds. The company also intends to allow shareholders to hold a stake in those proceeds. Ascendiant Capital lifted its price target to $25, and CEO Dr. Steven Quay will speak on clinical trials at ARDD 2026.
Atossa Announces Stapled CVR Plan and Raises Price Target. Atossa Therapeutics has unveiled a plan to issue a stapled convertible voting rights (CVR) linked to potential rare pediatric disease priority review voucher proceeds. The company also intends to allow shareholders to hold a stake in those proceeds. Ascendiant Capital lifted its price target to $25, and CEO Dr. Steven Quay will speak on clinical trials at ARDD 2026.